These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. Chou ST; Patil R; Galstyan A; Gangalum PR; Cavenee WK; Furnari FB; Ljubimov VA; Chesnokova A; Kramerov AA; Ding H; Falahatian V; Mashouf L; Fox I; Black KL; Holler E; Ljubimov AV; Ljubimova JY J Control Release; 2016 Dec; 244(Pt A):14-23. PubMed ID: 27825958 [TBL] [Abstract][Full Text] [Related]
26. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma. Liu X; Chen X; Shi L; Shan Q; Cao Q; Yue C; Li H; Li S; Wang J; Gao S; Niu M; Yu R J Exp Clin Cancer Res; 2019 May; 38(1):219. PubMed ID: 31122294 [TBL] [Abstract][Full Text] [Related]
27. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502 [TBL] [Abstract][Full Text] [Related]
28. Aberrant Al-Ghabkari A; Huang B; Park M Cells; 2024 Jan; 13(3):. PubMed ID: 38334610 [TBL] [Abstract][Full Text] [Related]
29. Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma. Narayan RS; Gasol A; Slangen PLG; Cornelissen FMG; Lagerweij T; Veldman HYYE; Dik R; van den Berg J; Slotman BJ; Würdinger T; Haas-Kogan DA; Stalpers LJA; Baumert BG; Westerman BA; Theys J; Sminia P Mol Cancer Ther; 2018 Feb; 17(2):347-354. PubMed ID: 28958992 [TBL] [Abstract][Full Text] [Related]
30. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. Raizer JJ J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112 [TBL] [Abstract][Full Text] [Related]
31. Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors. Talele S; Zhang W; Chen J; Gupta SK; Burgenske DM; Sarkaria JN; Elmquist WF J Pharmacol Exp Ther; 2022 Oct; 383(1):91-102. PubMed ID: 36137710 [TBL] [Abstract][Full Text] [Related]
32. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells. Grinshtein N; Rioseco CC; Marcellus R; Uehling D; Aman A; Lun X; Muto O; Podmore L; Lever J; Shen Y; Blough MD; Cairncross GJ; Robbins SM; Jones SJ; Marra MA; Al-Awar R; Senger DL; Kaplan DR Oncotarget; 2016 Sep; 7(37):59360-59376. PubMed ID: 27449082 [TBL] [Abstract][Full Text] [Related]
33. Clinical activity of the Makhlin I; Salinas RD; Zhang D; Jacob F; Ming GL; Song H; Saxena D; Dorsey JF; Nasrallah MP; Morrissette JJ; Binder ZA; O'Rourke DM; Desai AS; Brem S; Bagley SJ CNS Oncol; 2019 Nov; 8(3):CNS43. PubMed ID: 31769726 [TBL] [Abstract][Full Text] [Related]
34. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648 [TBL] [Abstract][Full Text] [Related]
35. Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery. Brar HK; Jose J; Wu Z; Sharma M Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678688 [TBL] [Abstract][Full Text] [Related]
36. Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment. Rahban M; Joushi S; Bashiri H; Saso L; Sheibani V Front Chem; 2023; 11():1325214. PubMed ID: 38264122 [TBL] [Abstract][Full Text] [Related]
37. Small molecule tyrosine kinase inhibitors in glioblastoma. Kim G; Ko YT Arch Pharm Res; 2020 Apr; 43(4):385-394. PubMed ID: 32239429 [TBL] [Abstract][Full Text] [Related]
38. A Pt(IV)-conjugated brain penetrant macrocyclic peptide shows pre-clinical efficacy in glioblastoma. Jimenez-Macias JL; Lee YC; Miller E; Finkelberg T; Zdioruk M; Berger G; Farquhar CE; Nowicki MO; Cho CF; Fedeles BI; Loas A; Pentelute BL; Lawler SE J Control Release; 2022 Dec; 352():623-636. PubMed ID: 36349615 [TBL] [Abstract][Full Text] [Related]
39. Multi-ligand functionalized blood-to-tumor sequential targeting strategies in the field of glioblastoma nanomedicine. Martins C; Sarmento B Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1893. PubMed ID: 37186374 [TBL] [Abstract][Full Text] [Related]
40. Facile synthesis of lactoferrin conjugated ultra small large pore silica nanoparticles for the treatment of glioblastoma. Janjua TI; Ahmed-Cox A; Meka AK; Mansfeld FM; Forgham H; Ignacio RMC; Cao Y; McCarroll JA; Mazzieri R; Kavallaris M; Popat A Nanoscale; 2021 Oct; 13(40):16909-16922. PubMed ID: 34533167 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]